TrialClinical rheumatology2019

Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial.

Laura Bazzichi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.